Single‐patient analysis from the NFH cohort demonstrated that LIRA effectively identified NSCLC patients with low PD‐L1 expression who could benefit from ICI therapy, demonstrating its clinical translation value. Here, CD274 is linked to non-small cell lung carcinoma.